What is Esperion Therapeutics's net change in cash?

Esperion Therapeutics (ESPR) reported net change in cash of -$11.69M in Q1 2026.

How has Esperion Therapeutics's net change in cash changed year-over-year?

Esperion Therapeutics's net change in cash increased by 61.2% year-over-year, from -$30.13M to -$11.69M.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Esperion Therapeutics ESPR Net Change in Cash

Net Change in Cash at other companies

AmgenAMGN

$2.91B+192%

Regeneron PharmaceuticalsREGN

-$153.1M-125%

NewAmsterdam Pharma CompanyNAMS

-$31.05M-14.6%

Lexicon PharmaceuticalsLXRX

$3.76M+200%

Zevra Therapeutics, Inc.ZVRA

$33.19M+834%

Eton Pharmaceuticals, Inc.ETON

-$6.28M-353%

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's net change in cash?: Esperion Therapeutics (ESPR) reported net change in cash of -$11.69M in Q1 2026.
How has Esperion Therapeutics's net change in cash changed year-over-year?: Esperion Therapeutics's net change in cash increased by 61.2% year-over-year, from -$30.13M to -$11.69M.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.